公开(公告)号：US20170333428A1

公开(公告)日：2017-11-23

申请号：US15667212

申请日：2017-08-02

Applicant: AbbVie Inc.

Inventor： Christine Collins ,  Bo Fu ,  Abhishek Gulati ,  Jens Kort ,  Matthew Kosloski ,  Yang Lei ,  Chih-Wei Lin ,  Ran Liu ,  Federico Mensa ,  Iok Chan Ng ,  Tami Pilot-Matias ,  David Pugatch ,  Nancy S. Shulman ,  Rogert Trinh ,  Rolando M. Viani ,  Stanley Wang ,  Zhenzhen Zhang

IPC: A61K31/4985 ,  A61K31/454

CPC classification number: A61K31/4985 ,  A61K31/454 ,  A61K31/498 ,  A61K31/7072 ,  A61K2300/00

Abstract: The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents to a subject with HCV infection, wherein the treatment lasts for 12 weeks and does not include administration of either interferon or ribavirin, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof.